
Investors should be cautious of NVIDIA (NVDA), as its recent deal with OpenAI is viewed as a "late-stage bubble" signal and a form of financial engineering that could be artificially inflating its revenue. This powerful partnership, described as "Wintel times 10," also creates significant anti-trust risk that could negatively impact the stock. A potential contrarian opportunity may exist in Kenview (KVUE), the maker of Tylenol, which has seen its stock fall over 7% due to recent negative publicity. A strong crisis management response from the company to defend its brand could lead to a significant stock recovery for investors. As a general strategy, be highly skeptical of future mega-mergers and ensure your portfolio is well-diversified, as market gains are dangerously concentrated in just a few stocks.

By New York Magazine
Every Tuesday and Friday, tech journalist Kara Swisher and NYU Professor Scott Galloway offer sharp, unfiltered insights into the biggest stories in tech, business, and politics. They make bold predictions, pick winners and losers, and bicker and banter like no one else. After all, with great power comes great scrutiny. From New York Magazine and the Vox Media Podcast Network.